2026 年美國生命科學產業在 AI 驅動診斷與製藥交易推動下蓬勃發展
• 儘管面臨 NIH 預算削減和貿易威脅,2026 年美國生命科學產業在 AI 進步與重大製藥交易的推動下勢頭強勁。 • Karius 針對免疫功能受損患者的 AI 基因組測試在測試超過 10 萬個案例後,能透過分析數百萬條 DNA 序列讀取,在一天內多檢測出 50% 的病原體。 • 生物技術寒冬告終,在政府施政優先事項下,重心已轉向透過 AI、數據與精準療法實現預防性醫療。
txbiomed.org由 AI 驅動,附引用來源
關於 Pharma 的最新報導和分析。
• 儘管面臨 NIH 預算削減和貿易威脅,2026 年美國生命科學產業在 AI 進步與重大製藥交易的推動下勢頭強勁。 • Karius 針對免疫功能受損患者的 AI 基因組測試在測試超過 10 萬個案例後,能透過分析數百萬條 DNA 序列讀取,在一天內多檢測出 50% 的病原體。 • 生物技術寒冬告終,在政府施政優先事項下,重心已轉向透過 AI、數據與精準療法實現預防性醫療。
txbiomed.org• 該製藥公司先前曾停擺在英國的大規模項目,但現已承諾對兩個據點進行投資,由 Keir Starmer 宣布。 • 英國最大的製藥公司 AstraZeneca 表示將在英國投資 3 億英鎊,在去年暫停大規模項目後出現了驚人的轉折。 • 該製藥公司先前對英國的商業環境感到失望(包括 NHS 對新藥的提供情況及藥品定價),因此撤回了在英項目。閱讀更多...
theguardian.comUnder settlement, Sackler family will pay state, local and Native American tribal governments, individual victims and othersSign up for the Breaking News US email to get newsletter alerts in your inboxA judge is expected to sentence OxyContin maker Purdue Pharma to forfeit $225m to the US justice department on Tuesday, clearing the way for the company to finalize a settlement of thousands of lawsuits it faces over its role in the opioid crisis.The penalty was agreed to in a 2020 pact to resolve federal civil and criminal investigations it was facing. If the judge signs off, other penalties will not be collected in return for Purdue settling the other lawsuits. Continue reading...
theguardian.comProposal, a win for RFK Jr’s Maha movement, is a ‘first step’ toward tackling plastic pollution, advocates sayThe Environmental Protection Agency (EPA) proposed on Thursday to include microplastics and pharmaceuticals on a list of contaminants in drinking water for the first time, a step that could lead to new limits on those substances for water utilities.Lee Zeldin, the EPA administrator, said they are responding to Americans who have worried about plastics and pharmaceuticals in their drinking water. The gesture also aims to hand a win to health secretary Robert FKennedy Jr’s Maha movement, which for months has pressured Zeldin to further crack down on environmental contaminants. Continue reading...
theguardian.comHealth minister Mark Butler says federal government is ‘not negotiating’ when it comes to removing price protections on common medicationsGet our breaking news email, free app or daily news podcastAustralia will not cave in to pressure from pharmaceutical giants and the Trump administration by removing consumer price protections on common medications, the health minister, Mark Butler says.Donald Trump imposed a new 100% tariff on branded pharmaceuticals imported into the US overnight, Australian time, trying to force manufacturers to agree to drug-pricing deals or commit to making their products domestically. Continue reading...
theguardian.com• Eli Lilly announced the acquisition of Centessa Pharmaceuticals, a company developing treatments for excessive daytime sleepiness and neurological conditions, in a deal valued at up to $7.8 billion if certain conditions are met. • Centessa shares soared 44% on the news, while Lilly's stock rose 3.7%, helping offset broader market pressures from companies like McCormick. • The deal highlights Big Pharma's aggressive push into neuroscience amid rising demand for sleep disorder therapies, potentially boosting Lilly's pipeline.
barchart.com• Express Scripts added CARDAMYST (etripamil) nasal spray to its commercial national formularies effective March 27, 2026, expanding access for commercially insured patients. • The FDA-approved self-administered spray converts acute paroxysmal supraventricular tachycardia (PSVT) episodes to sinus rhythm in adults. • This coverage decision makes the first-in-class treatment broadly affordable across the U.S., improving cardiovascular care options.
investors.milestonepharma.com• The FDA issued an urgent safety alert on March 20, 2026, warning of counterfeit versions of semaglutide and tirzepatide circulating through unverified online retailers, with 47 adverse events reported including severe infections and allergic reactions. • Counterfeit products lack sterility assurance and may contain contaminated ingredients or incorrect dosing, posing serious health risks to consumers seeking weight loss or diabetes treatment. • The agency recommends patients obtain GLP-1 medications only through licensed pharmacies with valid prescriptions, emphasizing that legitimate suppliers require medical supervision.
fda.govAs outbreak in Kent claims the lives of two young people, experts advise against rushing to get a vaccinePharmacies in England are reporting a surge in demand for meningitis vaccines after an outbreak in Kent claimed the lives of two young people and left others in hospital.However experts have advised against rushing to get a jab, stressing public health authorities are best placed to determine if vaccinations are required – and for whom. Continue reading...
theguardian.com• Telix Pharmaceuticals resubmitted its New Drug Application to the U.S. FDA on March 16, 2026, for TLX101-Px (Pixclara®), a PET imaging agent targeting gliomas in adults and pediatrics. • The agent received Orphan Drug and Fast Track designations from the FDA due to its potential to address unmet needs in post-treatment glioma management, with 18F-FET PET already in international guidelines but no U.S.-approved equivalent. • Glioblastoma multiforme (GBM), the most common aggressive primary brain cancer, affects about 22,000 new U.S. cases yearly, with recurrence nearly universal and median survival of 12-15 months post-diagnosis.
prnewswire.com